RCM
DNTH icon

Riverhead Capital Management’s Dianthus Therapeutics DNTH Stock Holding History

Riverhead Capital Management’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-46
Closed -$9K – 1506
2018
Q3 		$9K Hold
46
– – ﹤0.01% 1549
2018
Q2 		$10K Buy
+46
New +$10.4K ﹤0.01% 1530

Other funds holding DNTH

TGI
TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $4.26B AUM 5.81% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

Riverhead Capital Management's DNTH Position: Q4 2018 in Review

Riverhead Capital Management sold out of Dianthus Therapeutics (DNTH) in Q4 2018, closing a stake of 46 shares — an estimated $9K sold.

Riverhead Capital Management first reported a position in DNTH in Q2 2018 and held it in 2 quarters. The position peaked at $10K in Q2 2018. 54 funds tracked by Wall St. Rank hold DNTH as of Q4 2018.

  • Riverhead Capital Management reported no remaining Dianthus Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Riverhead Capital Management sold 46 Dianthus Therapeutics shares in Q4 2018, an estimated $9K.
  • Riverhead Capital Management first reported a position in Dianthus Therapeutics in Q2 2018 and held it in 2 quarters.
  • Riverhead Capital Management's Dianthus Therapeutics position peaked at $10K in Q2 2018.
  • 54 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q4 2018.

Based on Riverhead Capital Management's 13F filing for Q4 2018, filed 13 Feb 2019.